Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

October 17, 2018 admin CEO Interview, Healthcare Comments Off on Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

tetra logo

 

 

 

Guy Chamberland

 

 

 

 

 

Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative.

Investor Presentation Deck

Tetra Investor Presentation

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.




Related Articles

CEO Interview

Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Cancer therapies addressing multi-billion markets

January 17, 2019 admin CEO Interview, Healthcare Comments Off on Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Cancer therapies addressing multi-billion markets

                  Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) CEO Interview with James F. Oliviero discussing clinical progress in company’s pipeline of cancer drugs, addressing multi-billion dollar markets. The company’s lead […]

Healthcare

CytoDyn (OTC: CYDY) Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer

January 13, 2020 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer

VANCOUVER, Washington, Jan. 13, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]

Healthcare

Hoth Therapeutics (NASDQ: HOTH) to Attend Benchmark’s 8th Annual Discovery 1×1 Conference

November 18, 2019 admin Healthcare, Newsmakers Comments Off on Hoth Therapeutics (NASDQ: HOTH) to Attend Benchmark’s 8th Annual Discovery 1×1 Conference

NEW YORK, Nov. 18, 2019  — Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, […]